CoChat

Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Abstract

Negative allosteric modulators (NAMs) of metabotropic glutamate receptor 5 (mGlu5) have potential for the treatment of psychiatric diseases including depression, fragile X syndrome (FXS), anxiety, obsessive-compulsive disorders, and levodopa induced dyskinesia in Parkinson's disease. Herein we report the optimization of a weakly active screening hit 1 to the potent and selective compounds chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]pyridine (basimglurant, 2) and 2-chloro-4-((2,5-dimethyl-1-(4-(trifluoromethoxy)phenyl)-1H-imidazol-4-yl)ethynyl)pyridine (CTEP, 3). Compound 2 is active in a broad range of anxiety tests reaching the same efficacy but at a 10- to 100-fold lower dose compared to diazepam and is characterized by favorable DMPK properties in rat and monkey as well as an excellent preclinical safety profile and is currently in phase II clinical studies for the treatment of depression and fragile X syndrome. Analogue 3 is the first reported mGlu5 NAM with a long half-life in rodents and is therefore an ideal tool compound for chronic studies in mice and rats.

Overview

Integrity signals

Registry

Crossref · 10.1021/jm501642c

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 45 references

Research works printed but not linked: 4

  1. Rodriguez A. L., 2007, Curr. Opin. Drug Discovery Dev., 10, 715
  2. Lindsley C. W., 2009, Curr. Opin. Drug Discovery Dev., 12, 446
  3. Lindemann L., 2014, Curr. Neuropharmacol., 12, 35
  4. Ametamey S. M., 2006, J. Nucl. Med., 47, 698

Cited by

See all 74

Metadata

Authors
Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., Pähler, A., Peters, J.-U., Petersen, A., Prinssen, E., Ricci, A., Rueher, D., Rueher, M., Schneider, M., Spurr, P., Stoll, T., Tännler, D., Wichmann, J., Porter, R. H., Wettstein, J. G., & Lindemann, L.
Affiliations
  • F. Hoffmann-La Roche AG (CH)
  • University of Basel (CH)
Corresponding author
Jaeschke, Georg
Venue
Journal of Medicinal Chemistry
Published
2015-02-02
Volume
58
Issue
3
Pages
1358-1371
ISSN
  • 0022-2623 (ISSN-L)
  • 1520-4804
OpenAlex
W2011170609
Cited by
66
References
45
Citations by year
2026: 4 · 2025: 2 · 2024: 3 · 2023: 8 · 2021: 4 · 2020: 2 · 2019: 8 · 2018: 6 · 2017: 12 · 2016: 7 · 2015: 10
FWCI
5.75
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Medicinal Chemistry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
Keywords
metabotropic glutamate receptor 5, negative allosteric modulators, CTEP, antidepressant drug discovery, fragile X syndrome, anxiety, depression, levodopa-induced dyskinesia, drug metabolism and pharmacokinetics, preclinical safety, structure-activity optimization
MeSH terms
Allosteric Regulation, Animals, Depression, Dose-Response Relationship, Drug, Fragile X Syndrome, Humans, Imidazoles, Macaca mulatta, Male, Mice, Inbred Strains, Pyridines, Structure-Activity Relationship, Molecular Structure, Rats, Sprague-Dawley, Rats, Wistar, Mice, Rats, Drug Discovery, Receptor, Metabotropic Glutamate 5

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases. https://app.cochat.ai/papers/10.1021/jm501642c
The paper
Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., David, B., Funk, C., Guba, W., Harrison, A., Hartung, T., Honer, M., Huwyler, J., Kuratli, M., Niederhauser, U., . . . Lindemann, L. (2015). Metabotropic Glutamate Receptor 5 Negative Allosteric Modulators: Discovery of 2-Chloro-4-[1-(4-fluorophenyl)-2,5-dimethyl-1 H -imidazol-4-ylethynyl]pyridine (Basimglurant, RO4917523), a Promising Novel Medicine for Psychiatric Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/jm501642c

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.